靶向CD84的新型嵌合抗原受体T细胞疗法治疗急性髓系白血病和T细胞急性淋巴细胞白血病
本文介绍了一种首创的靶向CD84的CART细胞疗法(CART84),用于治疗复发或难治性急性髓系白血病(AML)和T细胞急性淋巴细胞白血病(T-ALL)。CD84在白血病原始细胞上高表达,在造血干祖细胞(HSPC)上表达有限,在健康人体组织中基本不表达。CART84在体外和患者来源异种移植(PDX)模型中均表现出对AML和T-ALL细胞的有效细胞毒性,并在体外和人源化小鼠模型中清除原代白血病原始细胞,同时对CD34+ HSPC的细胞毒性低,提示骨髓毒性风险低。这些结果支持CD84作为AML和T-ALL的有希望靶点,并为即将开展的首次人体I/II期临床试验(EudraCT 2024-519966-31-00)奠定基础。
要点
- CD84在白血病原始细胞高表达,在HSPC表达有限,健康组织基本不表达。
- CART84在体外和PDX模型中对AML和T-ALL细胞有强细胞毒性。
- CART84对CD34+ HSPC细胞毒性低,提示骨髓毒性风险低。
核心结论
- CD84是治疗复发或难治性AML和T-ALL的有希望靶点,支持开展首次人体I/II期临床试验(EudraCT 2024-519966-31-00)。
研究设计与样本
- 临床前研究:开发靶向CD84的第二代CART细胞(CART84),在体外、PDX模型和人源化小鼠模型中进行评估。
主要发现
- CD84在白血病原始细胞上高表达,在HSPC上表达有限,在健康人体组织中基本不表达。
- CART84在体外和PDX模型中对AML和T-ALL细胞表现出强细胞毒性。
- CART84在体外和人源化小鼠模型中清除原代白血病原始细胞,同时对CD34+ HSPC细胞毒性低,提示骨髓毒性风险低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the remarkable clinical successes of chimeric antigen receptor (CAR) T-cell therapies in treating B-cell malignancies and multiple myeloma, similar outcomes have not been achieved in other indications. For patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), treatment options are limited, yet CART-cell therapies offer significant potential to address this unmet need. Here, we introduce a first-in-class CART-cell therapy targeting CD84, a novel antigen, for the treatment of R/R AML and T-ALL. CD84 is highly expressed on leukemic blasts, with limited expression on hematopoietic stem progenitor cells (HSPC), and is largely absent in healthy human tissues. Our second-generation CARTs targeting CD84 (CART84) demonstrate potent cytotoxicity against AML and T-ALL cells both in vitro and in vivo in patient-derived xenograft (PDX) models. Furthermore, CART84 eliminated primary leukemic blasts while exhibiting low cytotoxicity against CD34+ HSPC in vitro and in humanized mouse models in vivo, suggesting a low risk of myelotoxicity. These results support CD84 as a promising target for AML and T-ALL and provide the foundation for our upcoming first-in-human phase I/II clinical trial using CD84-directed CAR T cell therapy for patients with R/R AML and T-ALL (EudraCT 2024-519966-31-00).
引用
- Pérez-Amill L, Armand-Ugón M, Val-Casals M, et al. A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias. Leukemia. 2025. PMID: 40770072. doi:10.1038/s41375-025-02705-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。